Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
Not yet recruitingOBSERVATIONAL
Enrollment
120
Participants
Timeline
Start Date
April 1, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Conditions
Alzheimer's DiseaseMCI-AD, Early Stage Alzheimer's Disease
All Listed Sponsors
lead
First Hospital of China Medical University
OTHER
NCT06868030 - Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study | Biotech Hunter | Biotech Hunter